SIGLEC14 and breast carcinoma: Indeed, Siglec-5 was recently characterized as an inhibitor of T cell activation, and combining its targeting with Siglec-14 and Tamoxifen hormone therapy was suggested to enhance anti-tumor immunity in an in vitro breast cancer model (70, 71).